Devices and technology

The use of the Cambridge hybrid closed-loop insulin delivery system by older adults with type 1 diabetes mellitus is associated with “improved quality of life,” says an international team of researchers.

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

Use of the MiniMed 780G advanced hybrid closed-loop system leads to greater reductions in glycated hemoglobin levels than conventional treatment in people with poorly controlled type 1 diabetes, ADAPT study data show.

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.

Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.

Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.

Closed-loop insulin delivery with the open-source OpenAPS algorithm results in significantly better glucose control than sensor-augmented pump delivery in children and adults in the randomized CREATE trial.

The Omnipod 5 closed-loop, tubeless insulin delivery system has achieved good results in young children with type 1 diabetes over 12 months, with no cases of severe hypoglycemia or diabetic ketoacidosis recorded.

The iLet bionic pancreas closed-loop insulin delivery system provides good glucose control without the need for the user to count carbohydrates, show findings from the pivotal trial.

Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.

Italian researchers have compared outcomes of children and adults with type 1 diabetes using Medtronic MiniMed 780G and the Tandem Control IQ closed-loop insulin delivery systems in real-world practice.

Older adults with type 1 diabetes spend more time in target glucose range when using the Cambridge hybrid closed-loop insulin delivery system than when using sensor-augmented pump delivery, shows a randomized trial.

Researchers find that the type of benefits people with type 1 diabetes gain from hybrid closed-loop insulin delivery differs according to their baseline glycemic control.

Findings from the ORACL trial suggest that closed-loop insulin delivery results in better glycemic control than sensor-augmented pump therapy among older adults with longstanding type 1 diabetes.

A consensus statement published in The Lancet Diabetes & Endocrinology offers information and guidance for healthcare practitioners faced with a person using DIY closed-loop insulin delivery.

Hybrid closed-loop therapy significantly improves glycemic control and quality of life relative to continuous subcutaneous insulin infusion or multiple daily insulin injections in children and adolescents with type 1 diabetes, research shows.